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Parvovirus 4 (PARV4) is a DNA virus frequently associated
with human immunodeﬁciency virus (HIV) and hepatitis C
virus (HCV) infections, but its clinical signiﬁcance is
unknown. We studied the prevalence of PARV4 antibodies
in 2 cohorts of HIV- and HCV-infected individuals (n=
469) and the correlations with disease status. We found that
PARV4 infection frequently occurred in individuals
exposed to bloodborne viruses (95% in HCV-HIV coin-
fected intravenous drug users [IDUs]). There were no corre-
lations between PARV4 serostatus and HCV outcomes.
There was, however, a signiﬁcant association with early
HIV-related symptoms, although because this was tightly
linked to both HCV status and clinical group (IDU), the
speciﬁc role of PARV4 is not yet clear.
Parvovirus 4 (PARV4) is a recently discovered DNA virus of
the Parvoviridae family that infects human populations world-
wide [1–5]. It has been frequently found in intravenous drug
users (IDUs) [4, 6] but is uncommon in healthy individuals in
Western countries, suggesting parenteral transmission [4, 6].
Parvovirus 4 is associated with human immunodeﬁciency
virus (HIV) and hepatitis C virus (HCV) infections [3]; hence
we were interested in the effect PARV4 might have on disease
progression. Parvovirus 4 has been found in many tissues, in-
cluding the bone marrow of HIV-positive individuals [3] and
the liver of HCV-positive individuals [1, 7], but is also found
in plasma, cerebrospinal ﬂuid, skin, and myocardium [1, 2, 4,
6, 8]. Despite the detection of viral DNA in so many organs,
PARV4 has rarely been linked to speciﬁc symptoms, except
for a recent study linking PARV4 to encephalitis [8] and in
the individual in whom PARV4 was discovered, who pre-
sented symptoms including pharyngitis, vomiting, and arthral-
gias [2]. Determining a pathological association is problematic
because PARV4 is so frequently found in individuals bur-
dened with HCV- or HIV-related disease. However, as a
common coinfection with these pathogens, it may have an
important impact on clinical disease. This is of increased
importance in light of the recent examination of immune
responses to this virus [9]. This revealed sustained high-fre-
quency T-cell responses associated with an effector memory
phenotype consistent with persistent exposure to immuno-
genic viral antigen. Because the antigen can be expressed in
both lymphoid and hepatic tissues [3, 7], an impact on both
HCV and HIV pathogenesis is plausible.
We therefore studied the impact of PARV4 serostatus on
HCV- and HIV-related disease progression. To do this, we
tested for PARV4-speciﬁc antibodies in 2 prospective cohorts
of HCV- and HIV-infected individuals (mono- and coinfected).
Hepatitis C viral clearance, genotype, patient gender, age, ala-
nine amino-transferase (ALT) levels, tissue histology (ﬁbrosis),
CD4 slopes, and Centers for Disease Control and Prevention
(CDC) events were analyzed in relation to PARV4 serostatus.
METHODS
Study Subjects and Sample Collection
Local ethical approval (MREC/98/3/55 and http://www.shcs.
ch/30-study-design) and informed patient consent were ob-
tained for 2 cohorts, totaling 469 individuals (Table 1). The
ﬁrst, which consisted of 193 individuals from the Swiss HIV
cohort [10], was made up of 99 HIV-positive, HCV-negative
men who have sex with men (MSM) and 94 HIV-HCV coin-
fected IDUs. The ﬁrst sample taken at least 1 year after
the ﬁrst positive HIV serology was used in experiments. The
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Trent HCV cohort, was divided into 44 individuals who
cleared HCV vs 232 who became chronically infected and,
among chronically infected individuals, 143 who had persist-
ently mild liver ﬁbrosis (Ishak ﬁbrosis score always 0 or 1, 1–5
biopsies were taken per individual, across 1–25 years) vs 98
who progressed to severe ﬁbrosis (Ishak ﬁbrosis score 5 or 6).
The most recent plasma sample available was tested in this
latter cohort. Plasma samples were taken by each center and
frozen until required.
Serological Screening
Plasma samples from these individuals were tested in dupli-
cate for anti-PARV4 immunoglobulin G (IgG), as described
elsewhere [6].
CD4 Slopes and CDC Events
CD4 counts were available for 114 of 193 individuals of the
Swiss HIV cohort prior to antiretroviral therapy. CD4 slopes
were calculated using GraphPad Prism when at least 3 time
points were available, spanning 6 months minimum. CD4
counts were plotted relative to time (day 0 was the ﬁrst avail-
able sample date) to determine CD4 slopes, which were then
compared to PARV4 serostatus using Mann–Whitney tests.
Kaplan–Meier survival curves were drawn to compare time to
reach CDC-B and CDC-C events and death, deﬁned by the
CDC as hallmarks of HIV-related disease [11].
Statistical Analyses
Statistical analyses were carried out using the Mann–Whitney
test, Fisher’s exact test, and log rank (Mantel–Cox test) using
GraphPad Prism software. For more detailed statistic analyses
on the Trent HCV cohort, the open-source R software (http://
www.r-project.org) was used to perform a logistic regression
to analyze the simultaneous relationship of age, gender, main
risk factor (IDU or MSM), and ALT with PARV4 serostatus.
The HCV genotype was excluded because this information
was not available for all individuals. The log odds of being
PARV4 seropositive were modeled as a linear function of all
variables potentially affecting this. The formula was:
LogoddsðPARV4 serostatusÞ  age
þ gender þ main risk factor þ ALT
where “∼” implies relationship. The coefﬁcients of the model
have approximately normal distributions; therefore P values
were obtained to compare individual coefﬁcients. This analysis
was carried out on 263 individuals of the Trent HCV cohort
with complete data sets.
RESULTS
PARV4 Strongly Correlates With Intravenous Drug Use and Is
Linked to CDC-B Event Occurrence
To address whether PARV4 has an impact on HIV disease pro-
gression, PARV4 serostatus was determined in 193 individuals
from the Swiss HIV cohort (Table 1). First, we noted a striking
association between PARV4 status and clinical group. In the
HIV-positive, HCV-positive (IDU) group, a 95% prevalence of
PARV4 was observed, compared with only 11% in the HIV-
positive MSM group (P<.0001). We next analyzed CD4 slopes
in relation to PARV4 status using serial CD4 counts available
for 114 patients: 49 PARV4 IgG
− individuals with CD4 slopes
ranging from −41.3 to 5 cells/µL/month (median, −6.2), and 65
PARV4 IgG
+ individuals with CD4 slopes ranging from −32.6
to 7.6 CD4 cells/µl/month (median, −6.3; data not shown).
Using this approach we could not detect a difference in CD4
T cell decline between serologic groups (P =.8 9) .
As another robust indicator of HIV disease progression, we
assessed the occurrence of CDC-B and CDC-C events and death
in PARV4-seropositive and -seronegative groups (Figure 1). The
CDC-B symptoms were observed earlier in PARV4-seropositive
individuals (P=0.02). The association was not signiﬁcant for
CDC-C or death or between clinical groups (MSM vs IDU; data
not shown). Thus, we did observe a correlation between PARV4
serostatus and early HIV disease progression, but the very close
association between PARV4 serostatus, risk factor for HIV
Table 1. Demographic Data and Parvovirus 4 (PARV4) Seroprevalence
Cohort Main Risk Factor No. HCV HIV Gender, % Male HCV Genotype at Diagnosis PARV4 Serostatus
Swiss HIV
MSM 99 − + 100% N/A 11%
IDUs 94 + + 74% 60% genotype 1,
26% genotype 3
95%
Notthingham Trent
66% IDUs 276 + − 67% 40% genotype 1,
48% genotype 3
31%
Only 58 of 94 hepatitis C virus (HCV) genotypes for the Swiss HIV cohort were available. The percentages shown represent proportions of known genotypes.
Abbreviations: HIV, human immunodeficiency virus; IDUs, intravenous drug users; MSM, men who have sex with men; N/A, not applicable.
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ponents of risk difﬁcult to dissect.
PARV4 Infection Is Also Common in HCV Mono-Infected
Individuals
The prevalence of PARV4 was also studied in 276 HCV-posi-
tive, HIV-negative individuals from the Trent HCV cohort.
Thirty-one percent of individuals were PARV4 seropositive,
and 36% in the IDU subset were PARV4 seropositive.
To determine if PARV4 serostatus affects clinical outcome in
HCV-positive individuals, age, gender, HCV genotype, ALT
levels, and main risk factor (IDU or non-IDU) were compared.
No signiﬁcant difference was seen between PARV4-seropositive
and -seronegative individuals in gender, HCV genotype, age, or
ALT levels (P=.89, .64, .26, and .34 respectively). We did,
however, ﬁnd a strong association between PARV4 serostatus
and intravenous drug use as a risk factor (P =.0 1 ).
Next, the parameters of age, gender, ALT, and risk factor
were analyzed together with PARV4 serology using a logistic
regression framework. The results of this analysis show that
only the IDU risk group signiﬁcantly correlated with detection
of PARV4 IgG (P= .01).
PARV4 Does Not Affect the Progression of HCV-Related
Disease
To assess the impact of PARV4 infection on HCV disease pro-
gression, 276 individuals from the Trent HCV cohort were
grouped by clinical outcome. Study subjects were divided by
PCR status: either persistently positive (n =232) or always
negative (n= 44), an indication of spontaneous HCV clear-
ance. Thirty-six percent of individuals who had cleared HCV
were PARV4 seropositive vs 29% of individuals who remained
viremic (P=.37; data not shown).
Longitudinal biopsy data was available for 241 of these indi-
viduals. They were divided into those who maintained a mild
ﬁbrosis score (Ishak score 0 or 1 over time; n= 143) and those
who progressed to severe liver ﬁbrosis (Ishak score 5 or 6; n =
98). Twenty-nine percent of the individuals with mild ﬁbrosis
were PARV4 seropositive vs 31% of those with progressive
disease (P=.78; data not shown). Finally, the treatment
outcome of 131 individuals from the Trent HCV cohort was
compared with their PARV4 serostatus. No signiﬁcant differ-
ence was seen between patients who did not respond to treat-
ment or relapsed and those who had a sustained virological
response (P=.45; data not shown).
DISCUSSION
This study conﬁrms that PARV4 infection is common in
HCV-positive individuals, and even more so in HCV-positive
IDUs coinfected with HIV. Although PARV4 did not inﬂu-
ence HCV persistence, disease progression, or treatment re-
sponse, PARV4-seropositive HIV-infected subjects progressed
faster to HIV CDC-B symptoms than PARV4-seronegative
individuals. However, because this was tightly linked to both
HCV status and clinical group (IDU), the speciﬁc role of
PARV4 is not yet clear.
Thirty-one percent of the HCV-positive, HIV-negative indi-
viduals of the Trent HCV cohort were PARV4 seropositive.
This is in accordance with our previous study that found 26%
seropositivity in 84 HCV-infected individuals [9] and other
studies that tested for PARV4 IgG [6] or viral DNA directly
[12]. Parvovirus 4 infections are acute and resolve rapidly, fol-
lowed by complete or almost complete clearance of viremia
and only very low viral loads on reactivation [12]. Parvovirus
4 may therefore be relatively inefﬁciently transmitted com-
pared with HCV and HIV-1.
In the Swiss HIV cohort, a striking 95% of the HIV-positive,
HCV-positive IDUs were PARV4 seropositive. This is the
Figure 1. Time to progress to Centers for Disease Control and Prevention (CDC)-B events (A), CDC-C events (B), and death (C) in each parvovirus 4
(PARV4) serology group. All individuals from the Swiss HIV cohort were grouped for this study. Time is expressed in months since human immunodeﬁ-
ciency virus (HIV) seroconversion. Each survival curve was compared using log-rank (Mantel–Cox test), and P values are indicated adjacent to each
graph. * represents statistical signiﬁcance. A signiﬁcant difference was observed between PARV4 immunglobulin G (IgG) positive and IgG
− in the time
to progress to CDC-B events.
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studies reporting 55%–85% [6]. Together with only 11%
PARV4 seropositivity of the HIV-positive, HCV-negative
MSM and 31% in the Trent HCV cohort, these data strongly
indicate parenteral transmission of PARV4. Parvovirus 4 sero-
prevalence in HCV-positive, HIV-negative IDUs was still only
36%. This suggests that HIV infection in the Swiss cohort may
be a marker for a more highly exposed IDU subset, although
other factors such as differences in risk behavior, local epide-
miology, and also an impact of HIV infection itself may poten-
tially play a role. Parvovirus 4–speciﬁc antibodies were also
present in non-IDU MSM, albeit in fewer individuals, which
suggests unreported intravenous drug use or another trans-
mission route because all these individuals were also HCV
negative. The possibility of alternative routes of transmission is
strengthened by studies in HIV-positive MSM [6], along with
reports of the presence of PARV4 in the general population in
Central Africa and in children in India [5,8].
The study cohorts were not further analyzed for the rate of
PARV4 seroconversion. These are prospectively clinically
monitored groups, and the exposure rates do not necessarily
reﬂect an active IDU status. Further studies to deﬁne the inci-
dence of new PARV4 infections in active IDU cohorts are un-
derway, and these will help deﬁne the duration of viremia and
the timing of acquisition of antibody and T-cell responses.
These 2 cohorts have allowed us to study the relationship
between PARV4 serostatus and age, gender, ALT levels, HCV
genotype, HCV treatment outcome, and HCV or HIV disease
progression. Although we found no correlation between PARV4
seropositivity and HCV disease, signiﬁcant correlations were
found between PARV4 and early HIV disease–related symp-
toms. However, this clear association is tightly linked to both
HCV status and clinical group (IDU). Although there is clear
evidence that PARV4 DNA persists in tissues, we did not test
for viral DNA because PARV4 viremia is rarely detected [3].
Immunosuppression from HIV infection is known to accel-
erate HCV disease progression, linked to increased HCV loads
and local immune activation in the liver [13, 14]. In the case
of increased mortality in HCV-positive, HIV-positive cohorts,
it is clearly hard to distinguish the impact of HCV infection
per se and the impact of the associated risk factor of intrave-
nous drug use or even another coinfection such as PARV4.
The IDU proﬁle may also affect subject compliance to treat-
ment, which may allow the disease to progress faster.
The factors that determine HCV disease progression in those
chronically infected are more complex, although they do include
environmental factors such as alcohol use in addition to gender
and age. Although PARV4 infection did not have a signiﬁcant
impact in our relatively small, although well-deﬁned cohort,
larger prospective studies could address this further.
PARV4 remains an intriguing virus that is not associated
with clear symptoms. Further research on the pathogenesis of
PARV4 infection, especially acute infection, is warranted given
the extremely high prevalence of infection in HIV-positive,
HCV-positive IDUs and the profound and long-lived T-cell
responses elicited. Future studies to deﬁne its cellular and
tissue targets may well shed further light on its pathogenesis,
both as a single agent and in the context of coinfection.
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